Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

pfizerbrussels

Pfizer presents positive results in meningococcal disease late-stage trials

May 13, 2016 Research and Development Pfizer, Vaccine, late stage trials, meningococcal disease

Pfizer (NYSE: PFE) has announced results from two pivotal late-stage trials demonstrating the immunogenicity of Trumenba against invasive meningococcal B …
News
lab

EU approves Idelvion for haemophilia B treatment

May 13, 2016 Medical Communications, Research and Development CSL, EU, Idelvion, approval, haemophilia B

The European Commission has approved Idelvion, coagulation Factor IX (recombinant) for the treatment and prophylaxis of bleeding in patients with …
News
biogen_logo

Sobi, Biogen’s haemophilia B therapy gets European approval

May 13, 2016 Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi

Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …
News

Bayer terminates clinical trial for hypertension due to safety concerns

May 13, 2016 Medical Communications, Research and Development Bayer, clinical trial, deaths, pulmonary hypertension, riociguat, safety concerns

Bayer has terminated a Phase II trial evaluating riociguat in patients with pulmonary hypertension due to fears raised by an …
News
james_kehoe

Takeda appoints new chief financial officer

May 12, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, cfo, james kehoe

Takeda Pharmaceuticals has named James Kehoe its new chief financial officer. He will begin the role on June 15 2016, …
Appointment

Almost 9 in 10 CCGs not implementing NICE guidelines on antibiotic resistance

May 12, 2016 Research and Development, Sales and Marketing CCGs, NICE, antibiotic resistance, failure

The Patients Association has called on all Clinical Commissioning Groups (CCGs) to implement the National Institute for Health and Care …
News

BMS says Nice refuses backing for its immunotherapy Opdivo to treat lung cancer

May 12, 2016 Medical Communications, Research and Development, Sales and Marketing

The National Institute for Health and Care Excellence (Nice) has rejected US pharma firm Bristol-Myers Squibb’s (NYSE: BMY) immune-oncology drug …
News

Multiple myeloma treatment from BMS and AbbVie scores EU approval

May 12, 2016 Research and Development, Sales and Marketing AbbVie, BMS, EMA, EU, Empliciti, approval, bristl-myers squibb, elotuzumab, multiple myeloma

Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV) have announced that the European Commission has approved Empliciti (elotuzumab) for the …
News
azhqlondonweb

AstraZeneca says its trial drug for thyroid cancer granted US FDA orphan drug designation

May 12, 2016 Research and Development, Sales and Marketing AstraZeneca, Orphan Drug Designation, US FDA, drug trial, regulation

AstraZeneca (LSE: AZN) on Thursday said the US Food and Drug Administration (FDA) has granted Orphan Drug Designation its trial …
News
gsk_l_rgb

Nice backs GSK’s lupus drug Benlysta

May 11, 2016 Research and Development, Sales and Marketing GSK, NHS, NICE, regulation

The National Institute for Health and Care Excellence (Nice) has backed GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab) to treat lupus.  The …
News
sovaldi-web

Gilead’s Sovaldi gets Indian patent; critics call it “major blow” to patient access

May 11, 2016 Manufacturing and Production, Research and Development, Sales and Marketing India, harm, hepatitis, patent, patient access, sovaldi

Gilead has been granted a patent for its hepatitis C drug, Sovaldi (sofosbuvir), in India which has sparked dismay among …
News
santenpharma

Santen Pharmaceutical says eye allergy drug meets primary endpoints in Phase III trials

May 11, 2016 Research and Development, Sales and Marketing Eye Allergy, Santen Pharmaceutical, drug trial, phase III

Santen Pharmaceutical said late stage trials for its drug to treat an allergic eye condition in children met its primary …
News
allergan

Allergan to buy back $10 billion of stock, Q1 earnings rise

May 11, 2016 Research and Development, Sales and Marketing Allergan, Buy Back, Financial, Q1, earnings, results, revenue

Botox-maker Allergan (NYSE: AGN) said it plans to buy back as much as $10 billion in stock after completing the …
News
fda2outsideweb

FDA expands Imbruvica label with new survival data

May 11, 2016 Research and Development, Sales and Marketing AbbVie, FDA, Janssen, data, efficacy, expanded, imbruvica, label, late stage, phase III

The US Food and Drug Administration (FDA) has expanded the label of Imbruvica (ibrutinib) to include the data from recent …
News
gavel

Baxalta sues Chugai for haemophilia drug patent breach

May 11, 2016 Research and Development Baxalta, Chugai, breach, court, haemophilia, infringe, infringement, patent, sue, suing

Baxalta has taken Chugai Pharmaceuticals to the Tokyo district court, claiming that the Japanese company has infringed upon its patent …
News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026